PCSK9
Amgen Lowers List Price for Repatha for Everyone
Effective Dec. 31, 2019, evolocumab will be distributed exclusively at the 60% lower list price of $5,850 per year ...
OCTOBER 24, 2019
Abarca, Amgen Bet on PCSK9 Outcomes
Innovative pharmacy benefits manager (PBM) Abarca has entered into an outcomes-based contract for the proprotein ...
APRIL 11, 2018
FDA Approves Once-Monthly Dosing Option for Praluent
Alirocumab, a PCSK9 inhibitor, is indicated as an adjunct to diet and maximally tolerated statin therapy for the ...
APRIL 26, 2017
First PCSK9 Outcomes Data Pushed to 2017
Providers, payors and patients will have to wait a little longer for highly anticipated outcomes data on the new ...
JUNE 23, 2016
Cigna Signs Value-Based Deal To Cover PCSK9s
Cigna has signed value-based contracts for PCSK9 inhibitors, based on patient response.
JUNE 6, 2016
Amgen Wins Next Step in Patent Dance Over PCSK9 Drugs
Despite the win, the case is long from over; Sanofi and Regeneron plan to appeal.
MARCH 24, 2016
